(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 50.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Adc Therapeutics Sa's revenue in 2026 is $75,209,000.On average, 8 Wall Street analysts forecast ADCT's revenue for 2026 to be $10,375,203,555, with the lowest ADCT revenue forecast at $8,400,478,528, and the highest ADCT revenue forecast at $13,163,181,815. On average, 7 Wall Street analysts forecast ADCT's revenue for 2027 to be $18,896,214,512, with the lowest ADCT revenue forecast at $15,088,232,120, and the highest ADCT revenue forecast at $24,623,053,353.
In 2028, ADCT is forecast to generate $32,438,460,286 in revenue, with the lowest revenue forecast at $18,120,743,797 and the highest revenue forecast at $46,006,720,254.